Understanding how AIRE and certain immune cells affect tumor growth and immune response
Official title: Elucidating the Role of AIRE and Tumor Associated Aire-expressing Cells in Tumor Growth and Immune Evasion
Funded at University of California, San Francisco · NIH-11087455 · Data updated 2026-11-12
This study is looking at how a gene called AIRE and certain immune cells work together in tumors, to understand how cancer can hide from our immune system, with the hope of finding new ways to help the body fight cancer better.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2024 |
| Project end | March 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $42,057 |
| NIH project number | 5F31CA288017-02 |
| Project ID | NIH-11087455 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who may benefit from enhanced immune responses against their cancer.
✕Less likely to help
Patients with non-solid tumors or those who do not have an active immune response may not receive benefits from this research.
What this research studies
This research investigates the role of the Autoimmune Regulator gene (AIRE) and specific immune cells in the tumor microenvironment, focusing on how they influence tumor growth and the body's immune response to cancer. By studying these interactions, the research aims to uncover mechanisms that allow tumors to evade the immune system. The approach involves using advanced techniques to analyze immune cell populations in various tumor models, with the goal of identifying potential therapeutic targets to enhance anti-tumor immunity.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for improving cancer immunotherapy by targeting specific immune cells that inhibit anti-tumor responses.
How similar studies have gone: Previous research has shown promising results in targeting immune cells in the tumor microenvironment, suggesting that this approach could lead to significant advancements in cancer treatment.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Arvedson, Matthew — University of California, San Francisco
- Study coordinator: Arvedson, Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.